You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 1, 2024

Investigational Drug Information for AZD6738


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug AZD6738?

AZD6738 is an investigational drug.

There have been 35 clinical trials for AZD6738. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2015.

The most common disease conditions in clinical trials are Lung Neoplasms, Breast Neoplasms, and Neoplasms. The leading clinical trial sponsors are AstraZeneca, Samsung Medical Center, and Cancer Research UK.

There are five US patents protecting this investigational drug and forty-two international patents.

Recent Clinical Trials for AZD6738
TitleSponsorPhase
Ceralasertib Followed by Durvalumab and Nab-paclitaxel Combination in mTNBC PatientsAstraZenecaPhase 2
Ceralasertib Followed by Durvalumab and Nab-paclitaxel Combination in mTNBC PatientsIFOM, The FIRC Institute of Molecular OncologyPhase 2
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung CancerAstraZenecaPhase 2

See all AZD6738 clinical trials

Clinical Trial Summary for AZD6738

Top disease conditions for AZD6738
Top clinical trial sponsors for AZD6738

See all AZD6738 clinical trials

US Patents for AZD6738

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AZD6738 ⤷  Try a Trial Chemical compounds Astrazeneca AB (Sodertalje, SE) ⤷  Try a Trial
AZD6738 ⤷  Try a Trial Chemical compounds AstraZeneca AB (Sodertalje, SE) ⤷  Try a Trial
AZD6738 ⤷  Try a Trial Chemical compounds AstraZeneca AB (Sodertalje, SE) ⤷  Try a Trial
AZD6738 ⤷  Try a Trial Chemical compounds AstraZeneca AB (Sodertalje, SE) ⤷  Try a Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AZD6738

Drugname Country Document Number Estimated Expiration Related US Patent
AZD6738 Argentina AR081859 2030-06-11 ⤷  Try a Trial
AZD6738 Australia AU2011263491 2030-06-11 ⤷  Try a Trial
AZD6738 Brazil BR112012031561 2030-06-11 ⤷  Try a Trial
AZD6738 Canada CA2800203 2030-06-11 ⤷  Try a Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.